TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10819404

Group type: EXPERIMENTAL
Intervention: Filtered QRS duration (FQRSD)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Root mean square amplitude of the last 40 ms (RMS40)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: High frequency low amplitude signals less than 40 microV (HFLAS40)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Total QRS duration (TQRSD)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Power spectral density of the last 40 ms
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Late potential duration of time domain analogous analyses
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Spectral score variables (low slice correlation ratio)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Spectral score variables (spectral entropy)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Spectral score variables (interslice correlation mean)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Spectral score variables (interslice correlation SD)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Mean peaks per slice (replacing interslice correlation SD)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Overall reproducibility of time domain and time domain analogous variables
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Long-term reproducibility
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Reproducibility in women and younger people
Number of subjects: 121
Study: 9110921

Group type: EXPERIMENTAL
Intervention: Low-dose beta-hCG (2500-25000 IU/day)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: High-dose beta-hCG (25000-100000 IU/day)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Beta-hCG therapy
Number of subjects: 8
Study: 8478852

Group type: EXPERIMENTAL
Intervention: Pulsed electromagnetic fields (PEMF) treatment for osteoarthritis; 18 half-hour periods of exposure over about 1 month.
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo treatment (control group).
Number of subjects: 27
Study: 2823863

Group type: EXPERIMENTAL
Intervention: Extruded bran product (period B)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Bran-gluten-starch mixture (period A)
Number of subjects: 7
Study: 30678686

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 2000 mg/day
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) with combination nutraceutical treatment (CT) 2000 mg/day
Number of subjects: 181

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 181
Study: 27321772

Group type: EXPERIMENTAL
Intervention: TPD protocol (mixed drops: 4:3:3 ratio of 1% tropicamide, 10% phenylephrine, 0.1% diclofenac)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional protocol (1% tropicamide, 10% phenylephrine, 0.1% diclofenac in separate bottles)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: TPD protocol
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional protocol
Number of subjects: 30
Study: 25695686

Group type: EXPERIMENTAL
Intervention: Dermatome technique with soft tissue removal
Number of subjects: 47

Group type: COMPARATOR
Intervention: Linear incision with no soft tissue reduction
Number of subjects: 47
Study: 23432848

Group type: EXPERIMENTAL
Intervention: Probiotic fermented milk
Number of subjects: 197

Group type: COMPARATOR
Intervention: Control dairy product
Number of subjects: 197
Study: 21157394

Group type: EXPERIMENTAL
Intervention: Recreational weight training (RWT) participants
Number of subjects: 88

Group type: COMPARATOR
Intervention: Control group (no RWT participation)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 88
Study: 19414635

Group type: EXPERIMENTAL
Intervention: Recombinant human a-galactosidase A treatment for 5 months
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo treatment for 5 months
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Recombinant human a-galactosidase A treatment continued in open-label trial
Number of subjects: 58
Study: 17563216

Group type: EXPERIMENTAL
Intervention: Prize-based contingency management (CM)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 103
Study: 15386481

Group type: EXPERIMENTAL
Intervention: Almotriptan 200 mg
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Almotriptan 150 mg
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Almotriptan (various doses 5-200 mg)
Number of subjects: 23
Study: 11311845

Group type: EXPERIMENTAL
Intervention: Diabetes Education Program (DEPB)
Number of subjects: 2055

Group type: COMPARATOR
Intervention: Control group (no education)
Number of subjects: 2055
Study: 10092916

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen (HBO) treatment: Daily 100-minute treatments with 100% oxygen at 2.8 atmospheres absolute for three days (or six days for clinically abnormal patients).
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normobaric oxygen (NBO) treatment: Daily 100-minute treatments with 100% oxygen at 1.0 atmosphere absolute for three days (or six days for clinically abnormal patients).
Number of subjects: 0
Study: 7759785

Group type: EXPERIMENTAL
Intervention: Progesterone i.m. (50 mg/day)
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Human chorionic gonadotrophin (hCG) (2000 IU every three days)
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Progesterone vaginal cream (100 mg/day)
Number of subjects: 176

Group type: COMPARATOR
Intervention: Nothing (controls)
Number of subjects: 176
Study: 2310915

Group type: EXPERIMENTAL
Intervention: Intravenously injected contrast media (both peripheral and central injection)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Contrast medium with varying osmolality
Number of subjects: 0
Study: 44124

Group type: EXPERIMENTAL
Intervention: Lormetazepam 0.0635 to 0.5 mg/70 kg
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Lormetazepam 1 mg/70 kg
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Lormetazepam 2‐4 mg/70 kg
Number of subjects: 21
Study: 31860604

Group type: EXPERIMENTAL
Intervention: Patients fulfilling all criteria for eCPR
Number of subjects: 92

Group type: COMPARATOR
Intervention: Patients not fulfilling all criteria for eCPR
Number of subjects: 92
Study: 31154805

Group type: EXPERIMENTAL
Intervention: Late winter (n=98)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Late summer (n=52)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Children aged 24-48 months
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Children not using formula milk
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Children not adhering to supplementation guidelines
Number of subjects: 150
Study: 28750015

Group type: EXPERIMENTAL
Intervention: Self-collected vaginal dry swabs (s-DRY)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Physician-collected cervical sampling (dr-WET)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Cobas HPV test
Number of subjects: 150

Group type: COMPARATOR
Intervention: Comparison of s-DRY and dr-WET
Number of subjects: 150
Study: 26639093

Group type: EXPERIMENTAL
Intervention: CO2 insufflation
Number of subjects: 205

Group type: COMPARATOR
Intervention: Air insufflation
Number of subjects: 205
Study: 23298271

Group type: EXPERIMENTAL
Intervention: Vinorelbine and cisplatin (Navelbine and platinum [NP]) with rh-endostatin
Number of subjects: 74

Group type: COMPARATOR
Intervention: Single NP chemotherapy
Number of subjects: 74
Study: 21910341

Group type: EXPERIMENTAL
Intervention: Hormone treatment (Group B)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Astragalus treatment (Group A)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Combined treatment of astragalus and hormone (Group C)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: All groups (A, B, C)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Group C vs Group B after treatment
Number of subjects: 90
Study: 19822977

Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg/day
Number of subjects: 140

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study: 16986348

Group type: EXPERIMENTAL
Intervention: Aromatase inhibitors (AIs) such as anastrozole, letrozole, and exemestane
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bisphosphonates (oral and intravenous) such as alendronate, risedronate, ibandronate, pamidronate, and zoledronic acid
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Baseline and annual follow-up bone density monitoring
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bisphosphonate therapy
Number of subjects: 0
Study: 14570792

Group type: EXPERIMENTAL
Intervention: Epidural morphine (2 mg, 2 ml) + i.t. normal saline
Number of subjects: 53

Group type: COMPARATOR
Intervention: Intrathecal morphine (0.075 mg, 1 ml) + ED normal saline
Number of subjects: 53
Study: 11019424

Group type: EXPERIMENTAL
Intervention: Diovan (80-160 mg/day for 8 weeks)
Number of subjects: 15
Study: 8776154

Group type: EXPERIMENTAL
Intervention: Needle-free injection with the Biojector
Number of subjects: 0

Group type: COMPARATOR
Intervention: Needle and syringe injections
Number of subjects: 0
Study: 1355875

Group type: EXPERIMENTAL
Intervention: Low haematocrit group (target haematocrit of 37‐38%) with 1‐4 phlebotomies
Number of subjects: 50

Group type: COMPARATOR
Intervention: High haematocrit group (target haematocrit of 41‐42%) with 0‐3 phlebotomies
Number of subjects: 50
Study: 6130246

Group type: EXPERIMENTAL
Intervention: Sodium stibogluconate 20 mg/kg body weight (higher dose)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sodium stibogluconate 10 mg/kg body weight (lower dose)
Number of subjects: 0
Study: 3942368

Group type: EXPERIMENTAL
Intervention: PY 108-068 (150 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: PY 108-068
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 29685013

Group type: EXPERIMENTAL
Intervention: LL-37 in TB group (7.45±1.58)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: TNF in TB group (8.51±1.92)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Vitamin D levels in TB group (24.18±1.95)
Number of subjects: 46
Study: 27063308

Group type: EXPERIMENTAL
Intervention: FiltekTM P90
Number of subjects: 52

Group type: COMPARATOR
Intervention: FiltekTM Z350 XT
Number of subjects: 52
Study: 25055142

Group type: EXPERIMENTAL
Intervention: Active stimulation at 1 mA
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Active stimulation at 2 mA
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 40
Study: 21890814

Group type: EXPERIMENTAL
Intervention: Aspirin 160 mg/day
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: Aspirin 300 mg/day
Number of subjects: 272

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 272
Study: 20047916

Group type: EXPERIMENTAL
Intervention: Ethanol hand sanitizers with organic acids
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ethanol hand sanitizers without organic acids
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hand washing with soap and water
Number of subjects: 0
Study: 18689181

Group type: EXPERIMENTAL
Intervention: TST using Assufil
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: TST using Monofil
Number of subjects: 40

Group type: COMPARATOR
Intervention: TST (both groups)
Number of subjects: 40
Study: 16393327

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (100 microg twice daily into each nostril for 7 days)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Matched placebo (twice daily into each nostril for 7 days)
Number of subjects: 13
Study: 14652007

Group type: COMPARATOR
Intervention: GGC repeat in Japanese population (73.7% had 16 repeats)
Number of subjects: 398

Group type: COMPARATOR
Intervention: GGC repeat in Caucasian population (53.3% had 16 repeats)
Number of subjects: 398

Group type: COMPARATOR
Intervention: GGC repeat in Japanese population (3.8% had 17 repeats)
Number of subjects: 398

Group type: COMPARATOR
Intervention: GGC repeat in Caucasian population (36.2% had 17 repeats)
Number of subjects: 398

Group type: COMPARATOR
Intervention: No Japanese had more than 18 GGC repeats
Number of subjects: 398

Group type: COMPARATOR
Intervention: CAG repeats in Japanese population
Number of subjects: 398

Group type: COMPARATOR
Intervention: CAG repeats in Caucasian population
Number of subjects: 398
Study: 11072056

Group type: EXPERIMENTAL
Intervention: Referred patients (n=41)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Screen-identified patients (n=69)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 110
Study: 8851900

Group type: EXPERIMENTAL
Intervention: Single task exposure (90-min English language transcription task)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Nontask control (90-min reading)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Repeated exposure to cognitive task until late at night
Number of subjects: 46

Group type: COMPARATOR
Intervention: Relaxed wakefulness
Number of subjects: 46
Study: 1310456

Group type: EXPERIMENTAL
Intervention: Two puffs from MDI (90 micrograms per puff)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 2.5 mg of nebulizer solution (delivered in 2 ml of buffered saline)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 6434911

Group type: EXPERIMENTAL
Intervention: slow, conventional four‐day method
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: more rapid introduction protocol
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: nasoenteric solutions
Number of subjects: 50
Study: 31842188

Group type: EXPERIMENTAL
Intervention: Experimental cohort (223 patients) using the PRoFiT‐NU Score for predicting poor functional outcomes.
Number of subjects: 328

Group type: EXPERIMENTAL
Intervention: Validation cohort (105 patients) assessed using the PRoFiT‐NU Score.
Number of subjects: 328
Study: 29587861

Group type: EXPERIMENTAL
Intervention: CoQ10 pre-treatment for 60 days preceding IVF-ICSI cycle
Number of subjects: 169

Group type: COMPARATOR
Intervention: No pre-treatment (Control)
Number of subjects: 169
Study: 27206690

Group type: EXPERIMENTAL
Intervention: Low-dose group (3 to 7 spheroids/cm²)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Medium-dose group (10 to 30 spheroids/cm²)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: High-dose group (40 to 70 spheroids/cm²)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: All patients
Number of subjects: 75

Group type: COMPARATOR
Intervention: Overall KOOS
Number of subjects: 75
Study: 24981149

Group type: EXPERIMENTAL
Intervention: Transdermal gel-based male hormonal contraceptive regimen (testosterone and Nestorone® gels)
Number of subjects: 79
Study: 26286977

Group type: EXPERIMENTAL
Intervention: Self-affirmation manipulation
Number of subjects: 86
Study: 20447094

Group type: EXPERIMENTAL
Intervention: 500-mL water drinking test (WDT)
Number of subjects: 15

Group type: COMPARATOR
Intervention: 1000-mL water drinking test (WDT)
Number of subjects: 15
Study: 18990045

Group type: EXPERIMENTAL
Intervention: Exercise and vibration (EVG)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Exercise (EG)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control (CG)
Number of subjects: 36
Study: 15910140

Group type: EXPERIMENTAL
Intervention: Performance of altruistic citizenship behavior by men
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Withholding of altruistic citizenship behavior by women
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Work-related altruism
Number of subjects: 0
Study: 12734634

Group type: EXPERIMENTAL
Intervention: 20 mg methylphenidate
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 40 mg methylphenidate
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 10985009

Group type: EXPERIMENTAL
Intervention: Educational sessions related to high-risk sexual behavior (4 peer-based, interactive sessions)
Number of subjects: 196
Study: 8841157

Group type: EXPERIMENTAL
Intervention: 80 mg valsartan
Number of subjects: 168

Group type: COMPARATOR
Intervention: 5 mg amlodipine
Number of subjects: 168
Study: 1737545

Group type: EXPERIMENTAL
Intervention: Topical 0.075% capsaicin applied 4 times/day
Number of subjects: 22

Group type: COMPARATOR
Intervention: Vehicle cream applied 4 times/day
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Follow-up open-label study
Number of subjects: 22
Study: 6608397

Group type: EXPERIMENTAL
Intervention: Vibratory stimulation and TENS
Number of subjects: 60

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 60
Study: 31535688

Group type: EXPERIMENTAL
Intervention: dCBT-I
Number of subjects: 658

Group type: COMPARATOR
Intervention: Control (online sleep education)
Number of subjects: 658
Study: 29611083

Group type: EXPERIMENTAL
Intervention: Golimumab treatment
Number of subjects: 3280
Study: 27583444

Group type: EXPERIMENTAL
Intervention: Flywheel leg-curl
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Nordic hamstring
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Russian belt deadlift
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Hip-extension conic-pulley
Number of subjects: 36
Study: 23838410

Group type: EXPERIMENTAL
Intervention: Hybrid fixation technique (1 u‐HA/PLLA plate and 4 monocortical screws and bicortical screw in each side)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Conventional plate fixation (1 u‐HA/PLLA plate and 4 monocortical screws in each side)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 44
Study: 26875224

Group type: EXPERIMENTAL
Intervention: Misoprostol (600 μg oral)
Number of subjects: 0
Study: 21040693

Group type: EXPERIMENTAL
Intervention: Maternal Mansonella perstans infection
Number of subjects: 1506

Group type: EXPERIMENTAL
Intervention: Tetanus immunisation during pregnancy
Number of subjects: 1506

Group type: EXPERIMENTAL
Intervention: Maternal BCG scar
Number of subjects: 1506

Group type: EXPERIMENTAL
Intervention: HIV exposure (HIV-exposed-uninfected infants)
Number of subjects: 1506

Group type: EXPERIMENTAL
Intervention: Infant malaria and HIV
Number of subjects: 1506
Study: 18412763

Group type: EXPERIMENTAL
Intervention: Stepped care smoking cessation program
Number of subjects: 322

Group type: COMPARATOR
Intervention: Brief contact care
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: Cessation services and mental health care
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: Cessation services
Number of subjects: 322
Study: 16187699

Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 12495134

Group type: EXPERIMENTAL
Intervention: New measures of the proportion of treatment effect explained by a surrogate marker
Number of subjects: 0

Group type: COMPARATOR
Intervention: Previous measures of surrogacy suggested by Freedman, Graubard, and Schatzkin
Number of subjects: 0
Study: 10088944

Group type: EXPERIMENTAL
Intervention: Flow cytometry using monoclonal antibodies (HLA‐ABC‐m3, GS145.2, FD705)
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: DNA typing
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Combination of flow cytometry and DNA typing
Number of subjects: 304
Study: 7770362

Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation
Number of subjects: 55

Group type: COMPARATOR
Intervention: Medical therapy (control group)
Number of subjects: 55
Study: 2349956

Group type: EXPERIMENTAL
Intervention: Short-term r‐HuEPO therapy (n = 4)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Long-term r‐HuEPO therapy (n = 8)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo therapy (n = 4)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: r‐HuEPO therapy (n = 8)
Number of subjects: 8
Study: 668524

Group type: EXPERIMENTAL
Intervention: Lidoflazine (up to 480 mg/24 h) followed by Propafenon (up to 1800 mg orally) for 4 days
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Propafenon followed by Lidoflazine for 4 days
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Combined success rate of both groups
Number of subjects: 60
Study: 31544469

Group type: EXPERIMENTAL
Intervention: Targeted acupuncture (TA)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Non-targeted acupuncture (NTA)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Male intervention (MI) group
Number of subjects: 30
Study: 31859961

Group type: EXPERIMENTAL
Intervention: 2 liters polyethylene glycol
Number of subjects: 74

Group type: COMPARATOR
Intervention: 4 liters polyethylene glycol
Number of subjects: 74
Study: 28816289

Group type: EXPERIMENTAL
Intervention: Rapid palatal expansion alone
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Alternating rapid palatal expansion and constriction
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 36
Study: 26436963

Group type: EXPERIMENTAL
Intervention: Therapeutic anticoagulation with warfarin
Number of subjects: 187

Group type: COMPARATOR
Intervention: Dual antiplatelet therapy
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Anticoagulation
Number of subjects: 187

Group type: COMPARATOR
Intervention: No anticoagulation
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Patients with reduced leaflet motion
Number of subjects: 187

Group type: COMPARATOR
Intervention: Patients with normal leaflet motion
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Patients with reduced leaflet motion (pooled registries)
Number of subjects: 187

Group type: COMPARATOR
Intervention: Patients with normal leaflet motion (pooled registries)
Number of subjects: 187
Study: 24016506

Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 18801

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 18801
Study: 20451345

Group type: EXPERIMENTAL
Intervention: PRISM-based joint protection education (PRISM-JP)
Number of subjects: 53
Study: 18433044

Group type: EXPERIMENTAL
Intervention: Extensive counseling based on current clinical practice guidelines
Number of subjects: 42

Group type: COMPARATOR
Intervention: Brief anti-smoking message
Number of subjects: 42
Study: 17067352

Group type: EXPERIMENTAL
Intervention: Less percent days abstinent (PDA)
Number of subjects: 1193

Group type: EXPERIMENTAL
Intervention: More drinks per drinking day (DDD)
Number of subjects: 1193

Group type: EXPERIMENTAL
Intervention: Up to 14 days of continuous abstinence before testing
Number of subjects: 1193

Group type: EXPERIMENTAL
Intervention: Years of drinking at dependence levels
Number of subjects: 1193

Group type: EXPERIMENTAL
Intervention: Previous treatment
Number of subjects: 1193

Group type: EXPERIMENTAL
Intervention: ADS and DrInC scores
Number of subjects: 1193